Developer docs
API playgroundTry for free, no card

Search company profiles

Revolution Contraceptives

Full company profile

uuid003aeru

Namestring
Revolution Contraceptives
Legal namestring
NEXT Life Sciences, Inc.
Websiteurl
vasalgel.org
Company typeenum
Private
Founded yearint
2013
Descriptiontext

NEXT Life Sciences, Inc. is a privately held, US-incorporated reproductive healthcare company that positions itself as serving couples seeking contraception and family planning solutions. Its corporate website carries the descriptor "Modern Reproductive Healthcare" and the tagline "Helping couples come together," with the primary customer persona articulated as couples needing reproductive healthcare. The company operates an associated consumer-facing brand, "Plan A For Men," hosted at planaformen.com, which is referenced as the company's solutions platform ("OUR SOLUTIONS" links to planaformen.com), suggesting a male-contraception product focus. The corporate site is a minimal Squarespace landing page with sections for Home, About/Team, News (linking to planaformen.com/news), Contact, and an email newsletter signup collecting first name, last name, and email — no e-commerce, product catalog, pricing, or distribution information is disclosed on the available source material.

The company's business model, product portfolio specifics, underlying technology, pricing, and revenue mechanics are not disclosed in the available source material. The homepage carries a regulatory disclaimer ("These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease"), which indicates the company is operating in a regulated medical product / device / pharmaceutical domain where FDA pathways are relevant — consistent with a contraceptive product in development or early commercialization. No headcount, funding history, ownership structure, leadership team, patents, partnerships, or named customers are disclosed. Operating geography, distribution channels, and revenue are all unstated. The single observable go-to-market motion is a top-of-funnel email newsletter capture on the corporate site, pointing to a direct-to-consumer awareness-building posture typical of an early-stage, pre-commercialization healthcare company.

Short descriptiontext

NEXT Life Sciences is a privately held US reproductive healthcare company targeting couples seeking contraception and family planning, operating through a corporate website and the associated consumer brand "Plan A For Men" (planaformen.com), with no disclosed products, pricing, or revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
reproductive healthcare products, contraceptive solutions, male contraception, family planning products, hormonal contraceptives
Industry1 code
PRIMARYHLAIADAK
Men’s Health (OTC Urologic & Sexual Health)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Reproductive Healthcare
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Revolution Contraceptives (operating as NEXT Life Sciences, Inc.) is a modern reproductive healthcare company that provides contraception and family planning solutions for couples, with its associated brand platform "Plan A For Men" (planaformen.com) suggesting a focus on male contraceptive products. The company positions itself around the tagline "Helping couples come together." Specific product SKUs, formulations, and technical product details are not publicly disclosed on the available source material.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NEXT Life Sciences is a modern reproductive healthcare company focused on helping couples. Based on the homepage content, the company offers solutions through its associated brand platform (planaformen.com). The specific products and services portfolio details are not available on this source page, as the homepage primarily serves as a corporate landing page with team information and newsletter signup functionality.

Product and service1 record
1Plan A For Men
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

YourChoice Therapeutics is developing a non-hormonal male contraceptive (YCT-529, a retinoic-acid receptor inhibitor). Same target indication (reversible male contraception), same customer (couples), and same competitive set.

TypeBroad incumbent
Description

Organon is a global women's health and reproductive-health pharmaceutical incumbent with established commercial infrastructure, hormonal contraceptives, and fertility brands. Comparable as the broad incumbent a successful male contraceptive would ultimately challenge or partner with.

TypeOthers
Description

Population Council is a nonprofit research organization that has historically led development of new contraceptive technologies (including longer-acting methods). Comparable as a developer/funder in the same R&D ecosystem and as a likely competitor or partner for early-stage contraceptive IP.

TypeDirect peer
Description

Veru is a pharma company with reproductive-health and contraceptive products (e.g., the FC2 female condom and the ENTADFI franchise), comparable as a small-cap, product-focused reproductive-health pharma peer addressing similar provider channels.

TypeBroad incumbent
Description

CooperSurgical is a large medical-device and fertility-services incumbent serving reproductive-health providers and patients. Comparable as a broad incumbent with established OB/GYN and fertility channels that a male contraceptive launch would need to access.

TypeDirect peer
Description

Contraline is developing a long-acting, reversible male contraceptive (ADAM hydrogel), directly comparable to a Plan A-style non-hormonal reversible male contraceptive in clinical-stage development. Competes in the same category with the same target end-user.

TypeDirect peer
Description

Eppin Pharma is developing a non-hormonal, reversible male contraceptive targeting the same unmet need that Revolution Contraceptives addresses. Closest comparable by indication, mechanism (non-hormonal), and target customer (couples seeking reversible male contraception).

TypeDirect peer
Description

Evofem commercializes Phexxi, a non-hormonal contraceptive for women, and is a directly comparable contraceptive-product peer in terms of regulatory pathway, prescriber model, and the non-hormonal reproductive-health positioning that distinguishes Revolution Contraceptives.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Revolution Contraceptives

Reproductive Healthcarevasalgel.org

NEXT Life Sciences is a privately held US reproductive healthcare company targeting couples seeking contraception and family planning, operating through a corporate website and the associated consumer brand "Plan A For Men" (planaformen.com), with no disclosed products, pricing, or revenue.

What Revolution Contraceptives does

NEXT Life Sciences, Inc. is a privately held, US-incorporated reproductive healthcare company that positions itself as serving couples seeking contraception and family planning solutions. Its corporate website carries the descriptor "Modern Reproductive Healthcare" and the tagline "Helping couples come together," with the primary customer persona articulated as couples needing reproductive healthcare. The company operates an associated consumer-facing brand, "Plan A For Men," hosted at planaformen.com, which is referenced as the company's solutions platform ("OUR SOLUTIONS" links to planaformen.com), suggesting a male-contraception product focus. The corporate site is a minimal Squarespace landing page with sections for Home, About/Team, News (linking to planaformen.com/news), Contact, and an email newsletter signup collecting first name, last name, and email — no e-commerce, product catalog, pricing, or distribution information is disclosed on the available source material.

The company's business model, product portfolio specifics, underlying technology, pricing, and revenue mechanics are not disclosed in the available source material. The homepage carries a regulatory disclaimer ("These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease"), which indicates the company is operating in a regulated medical product / device / pharmaceutical domain where FDA pathways are relevant — consistent with a contraceptive product in development or early commercialization. No headcount, funding history, ownership structure, leadership team, patents, partnerships, or named customers are disclosed. Operating geography, distribution channels, and revenue are all unstated. The single observable go-to-market motion is a top-of-funnel email newsletter capture on the corporate site, pointing to a direct-to-consumer awareness-building posture typical of an early-stage, pre-commercialization healthcare company.

Revolution Contraceptives firmographics

Firmographics
Name
Revolution Contraceptives
Legal name
NEXT Life Sciences, Inc.
Website
https://vasalgel.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
NEXT Life Sciences is a privately held US reproductive healthcare company targeting couples seeking contraception and family planning, operating through a corporate website and the associated consumer brand "Plan A For Men" (planaformen.com), with no disclosed products, pricing, or revenue.
Ownership category
akta.pro rank

Revolution Contraceptives industry classification

Industry
Product category
Reproductive Healthcare
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIADAK
Men’s Health (OTC Urologic & Sexual Health)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Reproductive healthcare products
  • Contraceptive solutions
  • Male contraception
  • Family planning products
  • Hormonal contraceptives

Where Revolution Contraceptives is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Revolution Contraceptives business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Marketing channels1 record

Revolution Contraceptives product offering

Product offering

Core offering

Revolution Contraceptives (operating as NEXT Life Sciences, Inc.) is a modern reproductive healthcare company that provides contraception and family planning solutions for couples, with its associated brand platform "Plan A For Men" (planaformen.com) suggesting a focus on male contraceptive products. The company positions itself around the tagline "Helping couples come together." Specific product SKUs, formulations, and technical product details are not publicly disclosed on the available source material.

Product overview

NEXT Life Sciences is a modern reproductive healthcare company focused on helping couples. Based on the homepage content, the company offers solutions through its associated brand platform (planaformen.com). The specific products and services portfolio details are not available on this source page, as the homepage primarily serves as a corporate landing page with team information and newsletter signup functionality.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plan A For Men

Companies that use Revolution Contraceptives

Customer profile

Segments1 record

Ideal customer profiles1 record

Revolution Contraceptives technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Revolution Contraceptives partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Revolution Contraceptives competitors and assessment

Company assessment

Direct peers

  • YourChoice Therapeutics: YourChoice Therapeutics is developing a non-hormonal male contraceptive (YCT-529, a retinoic-acid receptor inhibitor). Same target indication (reversible male contraception), same customer (couples), and same competitive set.
  • Veru Inc. Veru is a pharma company with reproductive-health and contraceptive products (e.g., the FC2 female condom and the ENTADFI franchise), comparable as a small-cap, product-focused reproductive-health pharma peer addressing similar provider channels.
  • Contraline: Contraline is developing a long-acting, reversible male contraceptive (ADAM hydrogel), directly comparable to a Plan A-style non-hormonal reversible male contraceptive in clinical-stage development. Competes in the same category with the same target end-user.
  • Eppin Pharma: Eppin Pharma is developing a non-hormonal, reversible male contraceptive targeting the same unmet need that Revolution Contraceptives addresses. Closest comparable by indication, mechanism (non-hormonal), and target customer (couples seeking reversible male contraception).
  • Evofem Biosciences: Evofem commercializes Phexxi, a non-hormonal contraceptive for women, and is a directly comparable contraceptive-product peer in terms of regulatory pathway, prescriber model, and the non-hormonal reproductive-health positioning that distinguishes Revolution Contraceptives.

Broad incumbents

  • Organon & Co. Organon is a global women's health and reproductive-health pharmaceutical incumbent with established commercial infrastructure, hormonal contraceptives, and fertility brands. Comparable as the broad incumbent a successful male contraceptive would ultimately challenge or partner with.
  • CooperSurgical: CooperSurgical is a large medical-device and fertility-services incumbent serving reproductive-health providers and patients. Comparable as a broad incumbent with established OB/GYN and fertility channels that a male contraceptive launch would need to access.

Others

  • Population Council: Population Council is a nonprofit research organization that has historically led development of new contraceptive technologies (including longer-acting methods). Comparable as a developer/funder in the same R&D ecosystem and as a likely competitor or partner for early-stage contraceptive IP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revolution Contraceptives social profiles

Digital presence

Revolution Contraceptives financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Revolution Contraceptives leadership team

Management profile

Number of profiles

Revolution Contraceptives funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Revolution Contraceptives M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revolution Contraceptives

What does Revolution Contraceptives do?

Revolution Contraceptives (operating as NEXT Life Sciences, Inc.) is a modern reproductive healthcare company that provides contraception and family planning solutions for couples, with its associated brand platform "Plan A For Men" (planaformen.com) suggesting a focus on male contraceptive products. The company positions itself around the tagline "Helping couples come together." Specific product SKUs, formulations, and technical product details are not publicly disclosed on the available source material.

Is Revolution Contraceptives a public or private company?

Revolution Contraceptives is a private company. It is classified as unknown and is currently operating.

When was Revolution Contraceptives founded?

Revolution Contraceptives was founded in 2013. It employs 1 to 10 people.

Where is Revolution Contraceptives based?

Revolution Contraceptives is headquartered in San Francisco, United States, in the North America region.

Who are Revolution Contraceptives's main competitors?

Direct peers on record are YourChoice Therapeutics, Veru Inc., Contraline, Eppin Pharma and Evofem Biosciences. Broad incumbents are Organon & Co. and CooperSurgical. Population Council is listed as an others.

Does Revolution Contraceptives have an API?

No public API is recorded for Revolution Contraceptives.

What industry is Revolution Contraceptives in?

Revolution Contraceptives's product category is Reproductive Healthcare. Its primary akta.pro industry code is HLAIADAK, Men’s Health (OTC Urologic & Sexual Health). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals